Yigal Dov Nochomovitz

“Hey, Todd, Tavo, and team, thank you for taking the questions, and also congrats on a very good momentum. I was also curious about Zoma. Obviously, you have a lot in the early stage pipeline.”

“I'm just wondering if you could be perhaps a little more specific with respect to the progress in Germany in terms of the quarter over quarter bile growth, the demand growth relative to the accrual process and what the headwind is on the accrual, given that starting in 2Q, I believe there was accrual throughout the…”

“And also, how much more can you say about what NOVO plans to do with 9851, you know, in terms of how it's going to be inserted into the development program, meaning in combo with the GLP-1 or for those perhaps not responding well enough or perhaps even as a maintenance therapy, you know, following the course of GLP-1…”

“Paracidemag is an asset you've been talking about more frequently recently. I would just love to get your thoughts on the recent data and wondering whether the profile that's emerging in the Phase 1 is exceeding your expectations.”

“I had one on Solspari and then one on Pagdibatnase. So I'm just curious, looking at the quarter on quarter trends from 3Q to 4Q, you were up 13% on revenue, and you were up just almost twice that on start forms.”